You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR088/#198  EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)

Citation Tools

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS16. Screening/Early detection
PR088/#198  EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Drescher C, Walter H, Pons-Tostivint E, et al
PR088/#198  EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)
International Journal of Gynecologic Cancer 2023;33:A80.